A long checklist can make a process look rigorous while directing attention away from the failures that matter most. Quality by design begins by asking what could compromise participant protection or the reliability of the study’s conclusions, then designing proportionate controls around those risks.
ICH E8(R1) is the core reference for this approach. The working exercise below applies it to biometrics planning without treating every study as if it has the same risk profile.
1. Identify the consequential evidence
List the data and decisions central to the study objective. Include endpoint measurement, treatment assignment, follow-up, population definitions, and critical safety information. Explain how failure in each area could affect interpretation.
For a hypothetical trial with a visit-based primary endpoint, assessment timing and completeness may deserve more attention than an administrative field with no analytical consequence. This does not mean ignoring other data; it means making priorities explicit.
2. Design controls before collection
Ask how a risk can be prevented, detected, and resolved. A difficult endpoint definition may require clearer collection instructions, training, and targeted review. Adding a late validation check does not necessarily repair information that was never collected correctly.
Bring clinical, operational, data-management, and statistical perspectives into the discussion. A mathematically elegant analysis can depend on follow-up that is infeasible for participants or sites. Identifying that tension early is part of quality design.
3. Connect signals to actions
A metric without an action pathway is only an observation. Define who reviews a signal, what contextual information is needed, and how a finding is escalated. Avoid automatic conclusions based on a threshold that has not been evaluated for the study.
The FDA’s risk-based monitoring Q&A provides additional context. Our recommendation is to document the rationale for each monitoring indicator and the review process that follows it.
4. Reassess as evidence accumulates
Risks can change when enrollment patterns, assessment performance, or vendor processes differ from expectations. Review the risk register at meaningful milestones and preserve the reason for changes. Do not let a document completed at startup become an unexamined artifact.
ICH E6(R3) is relevant to the broader quality-management context. For a practical biometrics review, connect critical risks to dataset checks, participant-level review, output diagnostics, and release decisions.
Quality by design is useful when it changes what the team does. It should make important assumptions visible, prevent avoidable problems, and direct qualified attention toward evidence that could change a conclusion. The measure of success is the usefulness of those controls, not the length of the checklist.
